Program
Tirapazamine
Also written as “tirapazamine” and “tirapazamine (SR259075)”.
Its studies are mostly in Carcinoma, Hepatocellular · Squamous Cell Carcinoma of Head and Neck · Carcinoma, Non-Small-Cell Lung · Head and Neck Neoplasms, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 30 open or running | phase 3since Jun 6, 2001 | Jun 6, 2001 | none ahead |
| Teclison | 21 open or running | phase 2since Jun 10, 2014 | Jun 10, 2014 | Mar 31, 2028phase 2 · NCT02174549 |
| Zhejiang Raygene Pharmaceuticals | 21 open or running | phase 3since Feb 19, 2025 | Feb 19, 2025 | Apr 1, 2029phase 3 · NCT06844357 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 6, 2001First study: phase 3 study in Lung NeoplasmsNew to SanofiSanofi · NCT00017459 · United States
- Oct 11, 2004Phase 3 study in Head and Neck NeoplasmsSanofi · NCT00094081 · 861 enrolled · United States
- Sep 13, 2005Phase 3 study in Squamous Cell Carcinoma of Head and NeckSanofi · NCT00174837 · 317 enrolled · United States, Argentina, Australia and more
- Jun 10, 2014Teclison's first study: phase 2 study in Carcinoma, HepatocellularNew to TeclisonTeclison · NCT02174549 · 25 planned · United States
- May 3, 2017Phase 2 study in Carcinoma, HepatocellularTeclison · NCT03145558 · 6 enrolled · United States
- Feb 19, 2025Zhejiang Raygene Pharmaceuticals's first study: phase 2 study in Carcinoma, HepatocellularNew to Zhejiang Raygene PharmaceuticalsZhejiang Raygene Pharmaceuticals · NCT06848556 · 16 enrolled · China
- Feb 19, 2025Phase 3 study in HCCZhejiang Raygene Pharmaceuticals · NCT06844357 · 300 planned · China
Ahead
- Mar 31, 2028Primary completion: phase 2 study in Carcinoma, HepatocellularTeclison · NCT02174549
- Apr 1, 2029Primary completion: phase 3 study in HCCZhejiang Raygene Pharmaceuticals · NCT06844357
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06848556Carcinoma, Hepatocellular · China | 2 | Terminated | Zhejiang Raygene Pharmaceuticals | Nov 6, 2023 | 16 |
| NCT06844357HCC · China | 3 | Recruiting | Zhejiang Raygene Pharmaceuticals | Apr 1, 2029 | 300 |
| NCT03145558Carcinoma, Hepatocellular · United States | 2 | Terminated | Teclison | Jun 30, 2024 | 6 |
| NCT02174549Carcinoma, Hepatocellular · United States | 2 | Recruiting | Teclison | Mar 31, 2028 | 25 |
| NCT00174837Squamous Cell Carcinoma of Head and Neck · United States, Argentina, Australia and more | 3 | Completed | Sanofi | Jan 2008 | 317 |
| NCT00094081Head and Neck Neoplasms · United States | 3 | Completed | Sanofi | Sep 2006 | 861 |
| NCT00017459Lung Neoplasms · United States | 3 | Completed | Sanofi |
How it is read
Names in the registry
- “Tirapazamine”, 3 entries
- “tirapazamine”, 3 entries
- “tirapazamine (SR259075)”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Hepatocellular, 3 studies
- Squamous Cell Carcinoma of Head and Neck, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Head and Neck Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.